Rheumatoid arthritis (RA) affects over 1.3 million adults in the U.S. and millions more globally, causing persistent joint pain, swelling, and irreversible bone damage if untreated. While methotrexate (MTX)—a first-line disease-modifying anti-rheumatic drug (DMARD)—helps many patients, up to 40% still experience worsening symptoms or bone destruction. A 2021 multicenter trial tested whether adding 99Tc-methylene diphosphonate (99Tc-MDP)—a drug used in China for RA and osteoporosis—to MTX could fill this gap for patients with moderate to severe disease.
The Study: A Gold-Standard Test of Combination Therapy
Led by Qiong Fu, Ping Feng, and colleagues from top Chinese medical institutions (including Renji Hospital, West China Hospital, and Nanjing Drum Tower Hospital), the trial was a double-blind, double-dummy randomized controlled trial (RCT)—the most reliable design for evaluating new treatments. Over 48 weeks, 178 MTX-naïve patients were split evenly into three groups:
- MTX + 99Tc-MDP combination (59 patients)
- MTX alone (59 patients)
- 99Tc-MDP alone (59 patients)
Researchers tracked two key outcomes:
- ACR20 response (a 20% improvement in joint pain, swelling, and function) by week 24.
- Modified Total Sharp Score (mTSS) (a measure of bone erosion and joint space narrowing on X-rays) by week 48.
The Results: Combination Therapy Beats Monotherapy
The combination of MTX and 99Tc-MDP outperformed both single-drug treatments—especially for symptom relief and bone protection:
1. Faster, More Effective Symptom Relief
By week 24, 69.5% of patients in the combo group achieved an ACR20 response—significantly higher than the 50.8% in the MTX alone group and 47.5% in the 99Tc-MDP alone group. The combo group also showed quicker improvement:
- Week 4: 35.5% had an ACR20 response (vs. 22% in MTX alone).
- Week 8: 54.2% (vs. 40.7% in MTX alone).
2. Dramatically Less Bone Damage
Bone destruction is RA’s most devastating complication—and 99Tc-MDP proved to be a powerful shield. Patients on the combo or 99Tc-MDP alone had far less radiographic progression (worsening bone damage) than those on MTX alone:
- 72.2% of combo patients had no increase in their mTSS (no new bone damage) by week 48.
- 60% of 99Tc-MDP alone patients had no progression.
- Just 36.4% of MTX alone patients avoided bone damage.
Even better: The combo group’s mTSS scores (a measure of total damage) stayed nearly flat, while MTX alone patients saw their scores rise—meaning more erosion and joint space loss.
Safety: No Serious Risks, Mild Side Effects
A critical win for 99Tc-MDP: no serious adverse events (SAEs) were reported across any group. The most common side effects—low white blood cell counts (WBC) or elevated liver enzymes—were mild and reversible. Fewer patients withdrew due to side effects in the 99Tc-MDP group (3.4%) compared to MTX alone (8.5%) or the combo (6.8%).
Why This Matters for RA Patients
RA’s biggest threat is irreversible bone destruction, driven by overactive osteoclasts (cells that break down bone). 99Tc-MDP— a bisphosphonate derivative—targets these cells to slow bone resorption. But unlike other bone-focused drugs (e.g., denosumab or traditional bisphosphonates), 99Tc-MDP also:
- Boosts regulatory T cells (Tregs)—immune cells that calm inflammation.
- Reduces pro-inflammatory proteins like TNF-α and IL-6, which drive joint damage.
This dual action means 99Tc-MDP doesn’t just ease pain—it stops the root cause of bone loss. For patients on MTX, adding 99Tc-MDP could be a game-changer—especially for those at high risk of bone damage.
Limitations to Consider
The trial has two key caveats:
- **Population Limitation: It only included Chinese patients with moderate to severe RA. Results may not apply to other ethnic groups or those with milder disease.
- Dosing: The 99Tc-MDP regimen (monthly for 3 months, then every 2 months) may not be optimal. Future studies could test higher or more frequent doses.
What This Means for RA Care
For patients struggling with MTX alone or at risk of bone damage, the combination of MTX + 99Tc-MDP offers a safe, effective alternative to slow RA’s progression. The trial also highlights 99Tc-MDP’s unique value: it’s one of the few drugs that targets both inflammation and bone destruction—addressing two of RA’s most harmful features in one treatment.
Fu Q, Feng P, Sun LY, et al. A double-blind, double-dummy, randomized controlled, multicenter trial of 99Tc-methylene diphosphonate in patients with moderate to severe rheumatoid arthritis. Chinese Medical Journal. 2021;134(12):1457–1464. doi:https://doi.org/10.1097/CM9.0000000000001527
Trial Registration: Chinese Clinical Trial Registry (ChiCTR-IPR-14005684)
Was this helpful?
0 / 0